Cargando…

Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally

Background: There are concerns that the use of antibiotics before, during or immediately after pregnancy may have adverse effects on the neonatal gut microbiome and adversely affect the development of the infant immune system, leading to the development of childhood allergy, asthma, atopic disease a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamont, Ronald F., Møller Luef, Birgitte, Stener Jørgensen, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043129/
https://www.ncbi.nlm.nih.gov/pubmed/32148773
http://dx.doi.org/10.12688/f1000research.19954.1
_version_ 1783501401119260672
author Lamont, Ronald F.
Møller Luef, Birgitte
Stener Jørgensen, Jan
author_facet Lamont, Ronald F.
Møller Luef, Birgitte
Stener Jørgensen, Jan
author_sort Lamont, Ronald F.
collection PubMed
description Background: There are concerns that the use of antibiotics before, during or immediately after pregnancy may have adverse effects on the neonatal gut microbiome and adversely affect the development of the infant immune system, leading to the development of childhood allergy, asthma, atopic disease and obesity. Methods: In this narrative review, we have explored a number of hypotheses, including the “Barker hypothesis”, the “hygiene hypothesis”, the link between inflammation and metabolic disease, and the influence of the neonatal gut microbiota on the development of the immune system in infants. Results: We found evidence to link the use of antibiotics before, during or immediately after pregnancy with an increased risk of childhood allergy, asthma, atopy and obesity. Conclusions : Although we found robust evidence to link antibiotic use in pregnancy with obesity and an “allergic triad” of asthma, eczema and hay fever, care must be taken when interpreting the findings because of the lack of adjustment for confounding variables in published studies. These may be (i) whether or not the mother had the same outcome variable (for example, asthma) as the infant, for which the mother may have received the antibiotics; (ii) the indication, timing or number of antibiotic courses given; (iii) the use of broad-spectrum or narrow-range antibiotics; (iv) the dose-dependent nature of the effector; and (v) the class of antibiotics used.
format Online
Article
Text
id pubmed-7043129
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-70431292020-03-05 Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally Lamont, Ronald F. Møller Luef, Birgitte Stener Jørgensen, Jan F1000Res Review Background: There are concerns that the use of antibiotics before, during or immediately after pregnancy may have adverse effects on the neonatal gut microbiome and adversely affect the development of the infant immune system, leading to the development of childhood allergy, asthma, atopic disease and obesity. Methods: In this narrative review, we have explored a number of hypotheses, including the “Barker hypothesis”, the “hygiene hypothesis”, the link between inflammation and metabolic disease, and the influence of the neonatal gut microbiota on the development of the immune system in infants. Results: We found evidence to link the use of antibiotics before, during or immediately after pregnancy with an increased risk of childhood allergy, asthma, atopy and obesity. Conclusions : Although we found robust evidence to link antibiotic use in pregnancy with obesity and an “allergic triad” of asthma, eczema and hay fever, care must be taken when interpreting the findings because of the lack of adjustment for confounding variables in published studies. These may be (i) whether or not the mother had the same outcome variable (for example, asthma) as the infant, for which the mother may have received the antibiotics; (ii) the indication, timing or number of antibiotic courses given; (iii) the use of broad-spectrum or narrow-range antibiotics; (iv) the dose-dependent nature of the effector; and (v) the class of antibiotics used. F1000 Research Limited 2020-02-25 /pmc/articles/PMC7043129/ /pubmed/32148773 http://dx.doi.org/10.12688/f1000research.19954.1 Text en Copyright: © 2020 Lamont RF et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lamont, Ronald F.
Møller Luef, Birgitte
Stener Jørgensen, Jan
Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
title Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
title_full Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
title_fullStr Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
title_full_unstemmed Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
title_short Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
title_sort childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043129/
https://www.ncbi.nlm.nih.gov/pubmed/32148773
http://dx.doi.org/10.12688/f1000research.19954.1
work_keys_str_mv AT lamontronaldf childhoodinflammatoryandmetabolicdiseasefollowingexposuretoantibioticsinpregnancyantenatallyintrapartumandneonatally
AT møllerluefbirgitte childhoodinflammatoryandmetabolicdiseasefollowingexposuretoantibioticsinpregnancyantenatallyintrapartumandneonatally
AT stenerjørgensenjan childhoodinflammatoryandmetabolicdiseasefollowingexposuretoantibioticsinpregnancyantenatallyintrapartumandneonatally